Q4 2025 Elutia Inc Earnings Call Transcript
Key Points
- Elutia Inc (ELUT) reported a 16% increase in revenue for the fourth quarter of 2025, reaching $3.3 million compared to $2.8 million in the same quarter last year.
- The company achieved a significant improvement in gross margins, with an adjusted gross margin of 66.8% for the fourth quarter, up from 56.5% in the prior year.
- Elutia Inc (ELUT) successfully submitted the NXT 41 product to the FDA, marking a key milestone in their product development pipeline.
- The company has a strong cash position with $44.4 million on hand, after paying off all outstanding senior debt, providing a solid financial foundation for future growth.
- Elutia Inc (ELUT) has been recognized as a 'Great Place to Work,' which enhances its ability to attract and retain top talent, contributing to its operational success.
- Elutia Inc (ELUT) reported a net loss from continuing operations of $6.5 million for the fourth quarter, slightly improved from a $7.2 million loss in the previous year.
- The company's adjusted EBITDA showed a loss of $4.2 million in the quarter, compared to a $3.4 million loss in the same period last year, indicating ongoing operational challenges.
- The approval timeline for NXT 41X is uncertain, with potential delays in FDA clearance, which could impact the product's market launch.
- Elutia Inc (ELUT) faces significant competition in the breast reconstruction market, which is valued at $1.5 billion, requiring strategic positioning to capture market share.
- The company is exploring strategic options for its Simpliderm product, which may lead to divestment and could impact its current revenue streams.
Good day everyone and welcome to Elutia 4th quarter 2025 financial results call. (Operator Instructions) Please note this conference is being recorded.
Now it's my pleasure to turn the call over to Sonali Fonseca. Please proceed.
Thank you, operator, and thank you all for participating in today's call. Earlier today, Elutia released financial results for the 4th quarter and full year ended December 31, 2025. A copy of the press release is available on the company's website.
Before we begin, I would like to remind you that management will make full statements during this call that include forward-looking statements. Within the meaning of the federal securities laws, which are pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995. All statements contained in this call that do not relate to matters of historical facts or relate to expectations or predictions of future events, results, or performance of forward-looking statements. All forward
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
